UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTSUnaudited Pro Forma Condensed Combined Financial Statements • June 26th, 2020 • Sonnet BioTherapeutics Holdings, Inc. • Pharmaceutical preparations
Contract Type FiledJune 26th, 2020 Company IndustrySonnet BioTherapeutics, Inc. (“Sonnet Sub”) and Chanticleer Holdings, Inc. (“Chanticleer” o the “Company”) entered into an Agreement and Plan of Merger dated October 10, 2019 (the “Merger Agreement”), by and among the Company, Sonnet Sub and Biosub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), as amended by Amendment No. 1 entered into as of February 7, 2020 (the “First Amendment”) (the Merger Agreement, as amended by the First Amendment, the “Amended Merger Agreement”) as approved on March 18, 2019, pursuant to which Merger Sub merged with and into Sonnet Sub, with Sonnet Sub surviving as a wholly-owned subsidiary of the Company (the “Merger”).
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTSUnaudited Pro Forma Condensed Combined Financial Statements • May 18th, 2020 • Sonnet BioTherapeutics Holdings, Inc. • Pharmaceutical preparations
Contract Type FiledMay 18th, 2020 Company IndustrySonnet BioTherapeutics, Inc. (“Sonnet Sub”) and Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”), formerly known as “Chanticleer Holdings, Inc.”, entered into an Agreement and Plan of Merger dated October 10, 2019 (the “Merger Agreement”), as amended by Amendment No. 1 thereto made and entered into as of February 7, 2020 (the “First Amendment”) (the Merger Agreement, as amended by the First Amendment, the “Amended Merger Agreement”) as approved by the Sonnet stockholders on March 18, 2020, pursuant to which Sonnet Sub became a wholly owned subsidiary of Sonnet (the “Merger”).
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTSUnaudited Pro Forma Condensed Combined Financial Statements • April 3rd, 2020 • Sonnet BioTherapeutics Holdings, Inc. • Retail-eating places
Contract Type FiledApril 3rd, 2020 Company IndustrySonnet BioTherapeutics, Inc. (“Sonnet Sub”) and Chanticleer Holdings, Inc. (“Chanticleer”) entered into an Agreement and Plan of Merger dated October 10, 2019 (the “Merger Agreement”), by and among the Company, Sonnet Sub and Biosub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), as amended by Amendment No. 1 entered into as of February 7, 2020 (the “First Amendment”) (the Merger Agreement, as amended by the First Amendment, the “Amended Merger Agreement”) as approved on March 18, 2019, pursuant to which Merger Sub merged with and into Sonnet Sub, with Sonnet Sub surviving as a wholly-owned subsidiary of the Company (the “Merger”).